Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Notre Dame Intermédica on Its R$2.7 Billion Equity Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame…
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is…
Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction,…
DexCom, Inc. $850 Million Convertible Notes Offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc…
Taiwan Liposome Company, Ltd. Initial Public Offering
Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public…
Orchard Therapeutics plc Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from…
Innovent Biologics, Inc. HK$3.15 Billion (US$403.1 Million) Initial Public Offering
Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong…
Gamida Cell Ltd. $50 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering…
Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of…